ReviewInflammopharmacology2025
Immuno-nutritional therapy in experimental autoimmune encephalomyelitis: a translational pathway to multiple sclerosis management.
Review in Inflammopharmacology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Depression and anxiety in inflammatory bowel disease: mechanisms and emerging therapeutics targeting the microbiota-gut-brain axis.Frontiers in immunology · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Multiple sclerosis (MS) is a chronic autoimmune disorder characterised by myelin degeneration in the central nervous system (CNS), leading to significant neurological impairment. Affecting approximately 2.8 million people globally and has a multifactorial aetiology involving genetic predispositions and environmental factors, particularly dietary influences. This review explores the emerging field of immuno-nutritional therapy as a novel approach for managing experimental autoimmune encephalomyelitis (EAE), a widely accepted animal model of MS. We highlight the therapeutic potential of key nutritional components, such as omega-3 fatty acids, polyphenols, and vitamins A and D, which have been shown to modulate immune responses and promote neuroprotection. These nutrients exert their effects by regulating cytokine profiles, enhancing regulatory T-cell (Treg) differentiation, and maintaining blood-brain barrier (BBB) integrity. Evidence suggests that dietary interventions can significantly modulate disease severity and progression in EAE, offering valuable insights into potential therapeutic strategies for MS patients. However, translating the findings from EAE models to human MS requires careful consideration of differences in immune responses and environmental factors. Future clinical trials designed to evaluate the long-term efficacy of dietary interventions across diverse MS populations are essential. By integrating immunomodulatory treatments with tailored nutritional strategies, there is a potential for innovative therapies that can alter disease trajectories and improve patient outcomes. A collaborative approach among nutrition scientists, immunologists, and neurologists could pave the way for effective immuno-nutritional therapies in MS management, enhancing the quality of life of those affected by this debilitating condition.
Indexed as
Identifiers
40528137What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.